title: Urinary concentration: different ways to open and close the tap.
abstract: Nephrogenic diabetes insipidus (NDI) provides an excellent model for the benefits and insights that can be gained from studying rare diseases. The discovery of underlying genes identified key molecules involved in urinary concentration, including the type 2 vasopressin receptor AVPR2 and the water channel AQP2, which constitute obvious pharmacologic targets. Subsequently developed drugs targeting AVPR2 not only provide potential benefit to some patients with NDI, but are now used for much more common clinical applications as diverse as nocturnal enuresis and heart failure. Yet, the story is still evolving: clinical observations and animal experiments continue to discover new ways to affect urinary concentration. These novel pathways can potentially be exploited for therapeutic gain. Here we review the (patho)physiology of water homoeostasis, the current status of clinical management, and potential new treatments.
authors.affiliation: UCL Institute of Child Health, Nephro-Urology and Great Ormond Street Hospital for Children NHS Foundation Trust, 30 Guildford Street, London, WC1N 3EH, UK, d.bockenhauer@ucl.ac.uk.
authors.forename: Detlef
authors.initials: D
authors.lastname: Bockenhauer
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Bichet
mesh_terms: D001834:Body Water / Q000378:metabolism; D002648:Child; D018500:Diabetes Insipidus, Nephrogenic / Q000235:genetics / Q000652:urine*; D006801:Humans; D007671:Kidney Concentrating Ability / Q000235:genetics*